Novel and Convergent Perspectives in Nanoparticle-Based Immunotherapy for Cancer
Novel and Convergent Perspectives in Nanoparticle-Based Immunotherapy for Cancer
Mohammadesmail Nikfar1
1) Associate Professor, Ph.D. in Mathematics, Department of Mathematics, School of Hekmat 1, District 4, Tehran, Iran.
IOI Code
:
AEZG-ACAEAF
Publication :
The 12th National Conference on Interdisciplinary Research in Management and Medical Sciences, Tehran(https://ircmms.ir/12th)
Abstract :
Designing nanovaccines capable of eliciting effective anti-tumor immunity requires an understanding of how the immune system senses and responds to threats, such as pathogens and tumors. Equally important is comprehending the mechanisms tumor cells employ to evade immune surveillance, as well as the detrimental effects that anti-tumor immune responses can exert on tumor progression—for instance, by driving the evolution of the tumor cell population toward phenotypes that are immunologically silent. The immune system and tumors are locked in a competitive "tug-of-war"; consequently, strategies focusing solely on enhancing anti-tumor immunity or inducing tumor cell death may prove therapeutically insufficient. Nanotechnology offers a unique opportunity to develop therapeutic agents that can simultaneously address both aspects, ultimately leading to tumor eradication. This review examines the current state of nanoparticle-based immunotherapy strategies for cancer—ranging from antigen or adjuvant delivery vehicles and artificial antigen-presenting cells to agents that directly target tumor-specific T lymphocytes. Insights gained from these studies not only facilitate the development of next-generation nanocarriers for drug delivery but also streamline the creation of nanoparticle-based therapeutic approaches designed to generate robust anti-tumor immunity. It has enhanced the understanding of the physical or chemical properties that influence the biodistribution, pharmacokinetics, and toxicology of tumor-targeting nanomedicines, and has paved the way for the development of next-generation compounds with superior therapeutic activity.
Keywords : cancer immunotherapy targeted drug delivery environment responsive nanoparticles tumor immune surveillance vaccines